PhaseRx Inc PZRXQ
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.02
- Shares Outstanding
- 11.69M
- Market Cap
- $11.69
- Volume/Avg
- 438 / 438
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 21
- Website
- http://www.phaserx.com
Valuation
|
Metric
|
PZRXQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PZRXQ
|
|---|---|
Quick Ratio | 1.93 |
Current Ratio | 2.14 |
Interest Coverage | −13.83 |
Quick Ratio
PZRXQ
Profitability
|
Metric
|
PZRXQ
|
|---|---|
Return on Assets (Normalized) | −99.85% |
Return on Equity (Normalized) | −218.49% |
Return on Invested Capital (Normalized) | −103.32% |
Return on Assets
PZRXQ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|ZQX@Tj | LOCK|J$l?x | $126B | |||
| Moderna Inc
MRNA
| LOCK|Z#ClzR | LOCK|wT | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|MzyjTD! | LOCK|$zxl | $80B | |||
| argenx SE ADR
ARGX
| LOCK|kljsKKq | LOCK|%& | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&qt&N>@ | LOCK|!z | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?hz#Z^ | LOCK|p@xr | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|FN>?>?wb | LOCK|dM#@v | $26B | |||
| Incyte Corp
INCY
| LOCK|SHxqw#R | LOCK|@! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@zXd!?Y | LOCK|$^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|fdCzcj< | LOCK|Sh | $14B |
United States